Bayer’s Pharmaceutical Ambitions Suffer Major Clinical Trial Setback

Bayer AG faces renewed pressure as a highly anticipated cardiovascular drug candidate failed to meet its primary endpoint in critical late-stage testing. The pharmaceutical giant’s shares declined significantly at the week’s opening, continuing their downward trajectory as investors reacted to this latest development.

The experimental heart failure treatment vericiguat, developed in partnership with Merck & Co., demonstrated disappointing results during its Phase III clinical study. The compound, which had shown considerable promise for treating heart insufficiency, fell short of achieving its main objectives. The negative outcome was particularly damaging as researchers presented the data at the prestigious European Society of Cardiology congress, amplifying the visibility of the failure.

This development represents more than a temporary Read more...

de | DE000BAY0017 | BAYER’S | boerse | 68163713 |